Overall, our data suggest a transcriptional signature of exaggerated adipose tissue dysfunction, which is linked to increased transcriptional activation of proteasomal degradation in muscle of patients with T2D as compared with obesity alone, and that the latter could be mediated by reduced expression and circulating levels of adiponectin, although a role for other adipokines or myokines cannot be ruled out. The gene discussed is ADIPOQ; the disease is obesity disorder.